Meanwhile, anti‐angiogenesis therapy can improve the effects of anti‐PD‐L1 treatment especially when it generates high endothelial venules that facilitate enhanced CTL infiltration and activity.81 The combination of bevacizumab and ipilimumab was reported to achieve a favorable response and can be safely administered together in patients with melanoma.82 Many more clinical trials of onco‐immune combination therapies are ongoing to provide a more effective strategy in cancer treatment. This evidence concerns the gene CD274 and cancer.